Building high-resolution synthetic lethal networks: A 'Google map' of the cancer cell

Trends in Molecular Medicine

Volumn 20, Issue 12, 2014, Pages 704-715

  Paul, James M ^a   Templeton, Shaina D ^a   Baharani, Akanksha ^a   Freywald, Andrew ^a   Vizeacoumar, Franco J ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b SASKATCHEWAN CANCER AGENCY   (Canada)

Author keywords

High resolution phenotypic interactions; Negative genetic interaction; Pooled shRNA and sgRNA screening; Synthetic dosage lethality; Synthetic lethality

Indexed keywords

CANCER CELL; CANCER GENETICS; CANCER THERAPY; GENE INTERACTION; GENETIC MANIPULATION; GENETIC SCREENING; GENOME; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEGATIVE GENETIC INTERACTION; NONHUMAN; REVIEW; BIOLOGICAL MODEL; CHROMOSOME MAP; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENE THERAPY; GENETIC ASSOCIATION; GENETICS; MULTIGENE FAMILY; MUTATION; NEOPLASMS; PROCEDURES; RNA INTERFERENCE; SYSTEMS BIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMOSOME MAPPING; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; GENETIC ASSOCIATION STUDIES; GENETIC TESTING; GENETIC THERAPY; HUMANS; MODELS, GENETIC; MULTIGENE FAMILY; MUTATION; NEOPLASMS; RNA INTERFERENCE; SYSTEMS BIOLOGY;

EID: 84915770945     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.09.009     Document Type: Review

References (99)

1. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
2. Sherbenou D.W., Druker B.J. Applying the discovery of the Philadelphia chromosome. J. Clin. Invest. 2007, 117:2067-2074.
3. Vogel C.L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
4. Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 2003, 3:459-465.
5. Montagut C., Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009, 283:125-134.
6. Chan D.A., Giaccia A.J. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat. Rev. Drug Discov. 2011, 10:351-364.
7. Collins I., Workman P. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2006, 2:689-700.
8. Kessler J.D., et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012, 335:348-353.
9. Liu L., et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012, 483:608-612.
10. Luo J., et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
11. Vizeacoumar F.J., et al. A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Mol. Syst. Biol. 2013, 9:696.
12. Dixon S.J., et al. Systematic mapping of genetic interaction networks. Annu. Rev. Genet. 2009, 43:601-625.
13. Kroll E.S., et al. Establishing genetic interactions by a synthetic dosage lethality phenotype. Genetics 1996, 143:95-102.
14. Tischler J., et al. Evolutionary plasticity of genetic interaction networks. Nat. Genet. 2008, 40:390-391.
15. Bernards R. A missing link in genotype-directed cancer therapy. Cell 2012, 151:465-468.
16. Bryant H.E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
17. Farmer H., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
18. Guha M. PARP inhibitors stumble in breast cancer. Nat. Biotechnol. 2011, 29:373-374.
19. Chapman P.B., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516.
20. Prahallad A., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
21. Corcoran R.B., et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012, 2:227-235.
22. Kirschner M. Marc Kirschner. Interview by Asher Mullard. Nat. Rev. Drug Discov. 2011, 10:894.
23. Hartwell L.H., et al. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997, 278:1064-1068.
24. McLellan J., et al. Synthetic lethal genetic interactions that decrease somatic cell proliferation in Caenorhabditis elegans identify the alternative RFC CTF18 as a candidate cancer drug target. Mol. Biol. Cell 2009, 20:5306-5313.
25. McManus K.J., et al. Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3276-3281.
26. Yu L., et al. Chemical-genetic profiling of imidazo[1,2-a]pyridines and -pyrimidines reveals target pathways conserved between yeast and human cells. PLoS Genet. 2008, 4:e1000284.
27. Bian Y., et al. Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:1628-1633.
28. van Pel D.M., et al. An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development. PLoS Genet. 2013, 9:e1003254.
29. van Pel D.M., et al. Saccharomyces cerevisiae genetics predicts candidate therapeutic genetic interactions at the mammalian replication fork. G3 (Bethesda) 2013, 3:273-282.
30. Sajesh B.V., et al. Synthetic lethal targeting of superoxide dismutase 1 selectively kills RAD54B-deficient colorectal cancer cells. Genetics 2013, 195:757-767.
31. Deshpande R., et al. A comparative genomic approach for identifying synthetic lethal interactions in human cancer. Cancer Res. 2013.
32. Byrne A.B., et al. A global analysis of genetic interactions in Caenorhabditis elegans. J. Biol. 2007, 6:8.
33. Tarailo M., et al. Synthetic lethal interactions identify phenotypic 'interologs' of the spindle assembly checkpoint components. Genetics 2007, 177:2525-2530.
34. Dixon S.J., et al. Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16653-16658.
35. Roguev A., et al. High-throughput genetic interaction mapping in the fission yeast Schizosaccharomyces pombe. Nat. Methods 2007, 4:861-866.
36. Li Z., et al. Systematic exploration of essential yeast gene function with temperature-sensitive mutants. Nat. Biotechnol. 2011, 29:361-367.
37. Sajesh B.V., et al. Synthetic genetic targeting of genome instability in cancer. Cancers 2013, 5:739-761.
38. Gurley K.E., Kemp C.J. Synthetic lethality between mutation in Atm and DNA-PK(cs) during murine embryogenesis. Curr. Biol. 2001, 11:191-194.
39. Morandell S., et al. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep. 2013, 5:868-877.
40. Cramer-Morales K., et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 2013, 122:1293-1304.
41. Nielsen T.O., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004, 10:5367-5374.
42. Reedijk M., et al. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat. 2008, 111:439-448.
43. Dong Y., et al. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res. 2010, 70:5465-5474.
44. Neshat M.S., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10314-10319.
45. +/- mice. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10320-10325.
46. Thomas G.V., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 2006, 12:122-127.
47. Reaper P.M., et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7:428-430.
48. Yang D., et al. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13836-13841.
49. Yang Y., et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012, 21:723-737.
50. Muellner M.K., et al. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat. Chem. Biol. 2011, 7:787-793.
51. Moffat J., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124:1283-1298.
52. Roguev A., et al. Quantitative genetic-interaction mapping in mammalian cells. Nat. Methods 2013.
53. Laufer C., et al. Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. Nat. Methods 2013.
54. Wang T., et al. Genetic screens in human cells using the CRISPR-Cas9 system. Science 2014, 343:80-84.
55. Shalem O., et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014, 343:84-87.
56. Bassik M.C., et al. A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell 2013, 152:909-922.
57. Cermelli S., et al. Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb. Perspect. Med. 2014, 4. 10.1101/cshperspect.a014209.
58. Kemp C.J., Grandori C. Functional genomics to identify unforeseen cancer drug targets. Future Oncol. 2013, 9:473-476.
59. Berns K., et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004, 428:431-437.
60. Paddison P.J., et al. A resource for large-scale RNA-interference-based screens in mammals. Nature 2004, 428:427-431.
61. Barrangou R., et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007, 315:1709-1712.
62. Nishimasu H., et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 2014, 156:935-949.
63. Zhang F., et al. CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum. Mol. Genet. 2014, 23(R1):R40-R46.
64. Koike-Yusa H., et al. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 2014, 32:267-273.
65. Pan X., et al. dSLAM analysis of genome-wide genetic interactions in Saccharomyces cerevisiae. Methods 2007, 41:206-221.
66. Marcotte R., et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2012, 2:172-189.
67. Scholl C., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
68. Babij C., et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 2011, 71:5818-5826.
69. Luo T., et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2860-2865.
70. Spoonamore J., et al. Screen for inhibitors of STK33 kinase activity. Probe Reports from the NIH Molecular Libraries Program 2010, National Center for Biotechnology Information (US), Bethesda (MD).
71. Weiwer M., et al. A potent and selective quinoxalinone-based STK33 inhibitor does not show synthetic lethality in KRAS-dependent cells. ACS Med. Chem. Lett. 2012, 3:1034-1038.
72. Sun C., et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 2014, 7:86-93.
73. Hoffman G.R., et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:3128-3133.
74. Bhinder B., Djaballah H. Systematic analysis of RNAi reports identifies dismal commonality at gene-level and reveals an unprecedented enrichment in pooled shRNA screens. Comb. Chem. High Throughput Screen. 2013, 16:665-681.
75. Bhinder B., et al. Discovery of a dicer-independent, cell-type dependent alternate targeting sequence generator: implications in gene silencing & pooled RNAi screens. PLoS ONE 2014, 9:e100676.
76. Bajrami I., et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 2014, 74:287-297.
77. Zhou P., et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 2014, 506:52-57.
78. Zender L., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008, 135:852-864.
79. Collins S.R., et al. Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map. Nature 2007, 446:806-810.
80. Roguev A., et al. Quantitative genetic-interaction mapping in mammalian cells. Nat. Methods 2013, 10:432-437.
81. Grandori C. A high-throughput siRNA screening platform to identify MYC-synthetic lethal genes as candidate therapeutic targets. Methods Mol. Biol. 2013, 1012:187-200.
82. Toyoshima M., et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:9545-9550.
83. Vizeacoumar F.J., et al. Integrating high-throughput genetic interaction mapping and high-content screening to explore yeast spindle morphogenesis. J. Cell Biol. 2010, 188:69-81.
84. Vizeacoumar F.J., et al. A picture is worth a thousand words: genomics to phenomics in the yeast Saccharomyces cerevisiae. FEBS Lett. 2009, 583:1656-1661.
85. Horn T., et al. Mapping of signaling networks through synthetic genetic interaction analysis by RNAi. Nat. Methods 2011, 8:341-346.
86. Laufer C., et al. Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. Nat. Methods 2013, 10:427-431.
87. Nijman S.M., Friend S.H. Cancer. Potential of the synthetic lethality principle. Science 2013, 342:809-811.
88. Costanzo M., et al. The genetic landscape of a cell. Science 2010, 327:425-431.
89. Liberali P., et al. A hierarchical map of regulatory genetic interactions in membrane trafficking. Cell 2014, 157:1473-1487.
90. Vogelstein B., et al. Cancer genome landscapes. Science 2013, 339:1546-1558.
91. Wood L.D., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
92. Wu X., Lippman S.M. An intermittent approach for cancer chemoprevention. Nat. Rev. Cancer 2011, 11:879-885.
93. Koonin E.V. Computational genomics. Curr. Biol. 2001, 11:R155-R158.
94. Kranthi T., et al. Identification of synthetic lethal pairs in biological systems through network information centrality. Mol. Biosyst. 2013, 9:2163-2167.
95. Eguchi T., et al. RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene. Oncogene 2007, 26:509-520.
96. Wang X., Simon R. Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med. Genomics 2013, 6:30.
97. Muller F.L., et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 2012, 488:337-342.
98. D'Antonio M., et al. Recessive cancer genes engage in negative genetic interactions with their functional paralogs. Cell Rep. 2013, 5:1519-1526.
99. Choung C.M., et al. SnapShot: branching morphogenesis. Cell 2014, 158:1199-1209.